U.S. Markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
84.37+0.27 (+0.32%)
At close: 4:02PM EDT

84.38 +0.01 (0.01%)
After hours: 4:19PM EDT

People also watch
Full screen
Previous Close84.10
Bid83.00 x 200
Ask86.00 x 100
Day's Range84.06 - 84.51
52 Week Range66.93 - 86.90
Avg. Volume1,958,310
Market Cap197.56B
PE Ratio (TTM)31.72
Earnings DateN/A
Dividend & Yield2.72 (3.27%)
Ex-Dividend Date2017-03-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • Ophthotech's Fovista Combo Regimen Disappoints in Phase III
    Zacks8 hours ago

    Ophthotech's Fovista Combo Regimen Disappoints in Phase III

    Ophthotech (OPHT) disappoints with poor evaluation of Fovista combined with Eylea or Avastin for treatment of AMD in phase III. The study misses the primary endpoint.

  • Zacks Small Cap Research8 hours ago

    CYRX: Raising Price Target on CAR-T Opportunity

    Cryoport (CYRX) reported Q2 2017 financial results.  Results continue to impress as revenue set another new high, extending that streak to 11 straight quarters.  Consistent increases in the number of clinical trials that the company supports remains the major catalyst to the topline growth.  That metric (i.e. Q2 revenue, at $2.9M, was up 52% yoy and inline with our $2.9M estimate.  It is also a new record and up almost 8% sequentially from Q1 (the prior best).  This is the fifth consecutive quarter in which revenue came in slightly better and operating loss much better than our respective estimates.  The $60k revenue difference in Q2 compared to our estimate relates to $36k beat ($2.22M A vs. $2.19M) in biopharma and $25k ($426k A vs. $401k E) beat in reproductive medicine, partially offset by $20k miss ($263k A vs. $283k E) in animal health.

  • Market Realistyesterday

    Pfizer’s Important Product Developments in 2Q17

    Pfizer’s (PFE) innovative health business and essential health business are focusing on growth. To strengthen the innovative health business, the company is focusing on the development of new drugs…